Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02773030 · OUTCOME

Overall Response Rate (ORR)

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · Source last updated 2026-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of Participants
Interval / dispersion
95% Confidence Interval
Time frame
On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks

What was measured

Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.

Analysis population: Safety Population

Groups in this outcome

Cohort A: Treatment 1

CC220 0.30mg

Cohort A: Treatment 2

CC220 0.45mg

Cohort A: Treatment 3

CC220 0.60mg

Cohort A: Treatment 4

CC220 0.75mg

Cohort A: Treatment 5

CC220 0.90mg

Cohort A: Treatment 6

CC220 1.0mg

Cohort B: Treatment 1

CC220 0.30mg + DEX

Cohort B: Treatment 2

CC220 0.45mg + DEX

Cohort B: Treatment 3

CC220 0.60mg + DEX

Cohort B: Treatment 4

CC220 0.75mg + DEX

Cohort B: Treatment 5

CC220 0.90mg + DEX

Cohort B: Treatment 6

CC220 1.0mg + DEX

Cohort B: Treatment 7

CC220 1.1mg + DEX

Cohort B: Treatment 8

CC220 1.2mg + DEX

Cohort B: Treatment 9

CC220 1.3.mg + DEX

Cohort B: Treatment 10

CC220 1.6mg + DEX

Cohort D: Treatment 1

CC220 + DEX

Cohort E: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort E: Treatment 2

CC220 1.1mg + DARA + DEX

Cohort E: Treatment 3

CC220 1.2mg + DARA + DEX

Cohort E: Treatment 4

CC220 1.3mg + DARA + DEX

Cohort E: Treatment 5

CC220 1.6mg + DARA + DEX

Cohort F: Treatment 1

CC220 1.0mg + BORT + DEX

Cohort F: Treatment 2

CC220 1.1mg + BORT + DEX

Cohort F: Treatment 3

CC220 1.3mg + BORT + DEX

Cohort F: Treatment 4

CC220 1.6mg + BORT + DEX

Cohort G: Treatment 1

CC220 1.1mg + CFZ + DEX

Cohort G: Treatment 2

CC220 1.3mg + CFZ + DEX

Cohort G: Treatment 3

CC220 1.6mg + CFZ + DEX

Cohort H1

CC220 + DEX

Cohort H2

CC220 + DEX

Cohort I

CC220 + DEX

Cohort J1: Treatment 1

CC220Vd 1.0mg + NE-ASCT

Cohort J1: Treatment 2

CC220Vd 1.6mg + NE-ASCT

Cohort K: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort K: Treatment 2

CC220 1.3mg + DARA + DEX

Cohort K: Treatment 3

CC220 1.6mg + DARA + DEX

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort A: Treatment 13
Cohort A: Treatment 23
Cohort A: Treatment 34
Cohort A: Treatment 46
Cohort A: Treatment 56
Cohort A: Treatment 67
Cohort B: Treatment 110
Cohort B: Treatment 23
Cohort B: Treatment 33
Cohort B: Treatment 43
Cohort B: Treatment 513
Cohort B: Treatment 613
Cohort B: Treatment 710
Cohort B: Treatment 88
Cohort B: Treatment 914
Cohort B: Treatment 1013
Cohort D: Treatment 1107
Cohort E: Treatment 13
Cohort E: Treatment 23
Cohort E: Treatment 35
Cohort E: Treatment 413
Cohort E: Treatment 526
Cohort F: Treatment 13
Cohort F: Treatment 27
Cohort F: Treatment 310
Cohort F: Treatment 49
Cohort G: Treatment 14
Cohort G: Treatment 28
Cohort G: Treatment 34
Cohort H16
Cohort H25
Cohort I41
Cohort J1: Treatment 11
Cohort J1: Treatment 217
Cohort K: Treatment 125
Cohort K: Treatment 225
Cohort K: Treatment 325

Reported measurements

Source class 1
Values in Percentage of Participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort A: Treatment 10Not reported0.070.8Not reported
Cohort A: Treatment 20Not reported0.070.8Not reported
Cohort A: Treatment 30Not reported0.060.2Not reported
Cohort A: Treatment 433.3Not reported4.377.7Not reported
Cohort A: Treatment 50Not reported0.045.9Not reported
Cohort A: Treatment 614.3Not reported0.457.9Not reported
Cohort B: Treatment 130.0Not reported6.765.2Not reported
Cohort B: Treatment 233.3Not reported0.890.6Not reported
Cohort B: Treatment 333.3Not reported0.890.6Not reported
Cohort B: Treatment 466.7Not reported9.499.2Not reported
Cohort B: Treatment 530.8Not reported9.161.4Not reported
Cohort B: Treatment 623.1Not reported5.053.8Not reported
Cohort B: Treatment 720.0Not reported2.555.6Not reported
Cohort B: Treatment 825.0Not reported3.265.1Not reported
Cohort B: Treatment 950.0Not reported23.077.0Not reported
Cohort B: Treatment 1030.8Not reported9.161.4Not reported
Cohort D: Treatment 126.2Not reported18.135.6Not reported
Cohort E: Treatment 10Not reported0.070.8Not reported
Cohort E: Treatment 233.3Not reported0.890.6Not reported
Cohort E: Treatment 320.0Not reported0.571.6Not reported
Cohort E: Treatment 461.5Not reported31.686.1Not reported
Cohort E: Treatment 553.8Not reported33.473.4Not reported
Cohort F: Treatment 133.3Not reported0.890.6Not reported
Cohort F: Treatment 242.9Not reported9.981.6Not reported
Cohort F: Treatment 370.0Not reported34.893.3Not reported
Cohort F: Treatment 466.7Not reported29.992.5Not reported
Cohort G: Treatment 175.0Not reported19.499.4Not reported
Cohort G: Treatment 250.0Not reported15.784.3Not reported
Cohort G: Treatment 375.0Not reported19.499.4Not reported
Cohort H166.7Not reported22.395.7Not reported
Cohort H220.0Not reported0.571.6Not reported
Cohort I34.1Not reported20.150.6Not reported
Cohort J1: Treatment 1100.0Not reported2.5100.0Not reported
Cohort J1: Treatment 282.4Not reported56.696.2Not reported
Cohort K: Treatment 196.0Not reported79.699.9Not reported
Cohort K: Treatment 2100.0Not reported86.3100.0Not reported
Cohort K: Treatment 388.0Not reported68.897.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.0
        upper Limit
        70.8
        value
        0
      2. group Id
        OG001
        lower Limit
        0.0
        upper Limit
        70.8
        value
        0
      3. group Id
        OG002
        lower Limit
        0.0
        upper Limit
        60.2
        value
        0
      4. group Id
        OG003
        lower Limit
        4.3
        upper Limit
        77.7
        value
        33.3
      5. group Id
        OG004
        lower Limit
        0.0
        upper Limit
        45.9
        value
        0
      6. group Id
        OG005
        lower Limit
        0.4
        upper Limit
        57.9
        value
        14.3
      7. group Id
        OG006
        lower Limit
        6.7
        upper Limit
        65.2
        value
        30.0
      8. group Id
        OG007
        lower Limit
        0.8
        upper Limit
        90.6
        value
        33.3
      9. group Id
        OG008
        lower Limit
        0.8
        upper Limit
        90.6
        value
        33.3
      10. group Id
        OG009
        lower Limit
        9.4
        upper Limit
        99.2
        value
        66.7
      11. group Id
        OG010
        lower Limit
        9.1
        upper Limit
        61.4
        value
        30.8
      12. group Id
        OG011
        lower Limit
        5.0
        upper Limit
        53.8
        value
        23.1
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      4
    4. group Id
      OG003
      value
      6
    5. group Id
      OG004
      value
      6
    6. group Id
      OG005
      value
      7
    7. group Id
      OG006
      value
      10
    8. group Id
      OG007
      value
      3
    9. group Id
      OG008
      value
      3
    10. group Id
      OG009
      value
      3
    11. group Id
      OG010
      value
      13
    12. group Id
      OG011
      value
      13
    units
    Participants
description
Tumor response, including progressive disease (PD) according to the IMWG Uniform Response Criteria (Kumar, 2016) for subjects who achieved partial response (PR) or better.
dispersion Type
95% Confidence Interval
groups
  1. description
    CC220 0.30mg
    id
    OG000
    title
    Cohort A: Treatment 1
  2. description
    CC220 0.45mg
    id
    OG001
    title
    Cohort A: Treatment 2
  3. description
    CC220 0.60mg
    id
    OG002
    title
    Cohort A: Treatment 3
  4. description
    CC220 0.75mg
    id
    OG003
    title
    Cohort A: Treatment 4
  5. description
    CC220 0.90mg
    id
    OG004
    title
    Cohort A: Treatment 5
  6. description
    CC220 1.0mg
    id
    OG005
    title
    Cohort A: Treatment 6
  7. description
    CC220 0.30mg + DEX
    id
    OG006
    title
    Cohort B: Treatment 1
  8. description
    CC220 0.45mg + DEX
    id
    OG007
    title
    Cohort B: Treatment 2
  9. description
    CC220 0.60mg + DEX
    id
    OG008
    title
    Cohort B: Treatment 3
  10. description
    CC220 0.75mg + DEX
    id
    OG009
    title
    Cohort B: Treatment 4
  11. description
    CC220 0.90mg + DEX
    id
    OG010
    title
    Cohort B: Treatment 5
  12. description
    CC220 1.0mg + DEX
    id
    OG011
    title
    Cohort B: Treatment 6
param Type
NUMBER
population Description
Safety Population
reporting Status
POSTED
time Frame
On Average of (Cohort A: 44.96, Cohort B: 32.79, Cohort D: 21.14, Cohort E: 53.74, Cohort F: 46.34, Cohort G: 63.26, Cohort H1: 58.10, Cohort H2: 22.11, Cohort I: 20.96, Cohort J: 86.21, Cohort K: 56.29) Weeks
title
Overall Response Rate (ORR)
type
SECONDARY
unit Of Measure
Percentage of Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice